ResMed Q1 FY2024 revenue up 16% to $1.10B; non-GAAP EPS $1.64 (+9% YoY)

RESMED INC

2024-Q1 EPS reported $1.49 revenue$1,102,321,000

Revenue $1,102.3M (+16% YoY); operating income $289.0M (+5%); non-GAAP operating profit +10%.
Diluted EPS $1.49 (GAAP) and $1.64 (non-GAAP, +9% YoY); gross margin 54.4%, down 250 bps.
Operating cash flow $286.3M; company expects to resume share repurchase program in upcoming quarter.
Board declared quarterly dividend of $0.48/share, payable Dec 14, record Nov 9.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RESMED INC reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On October 26, 2023, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-23-264072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.